77044
document
Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma . A prospective randomized study was conducted in 51 patients with stage D hormone-resistant prostatic carcinoma , comparing a combination of doxorubicin and lomustine ( DC ) with cyclophosphamide and 5-FU ( CF ) . Patients were assessed objectively ( employing National Prostate Cancer Project criteria ) and subjectively ( using a numerical scoring scheme ) . Each regimen was well tolerated with acceptable levels of myelosuppression . The objective partial response rate was 57 % for DC and 8 % for CF . Objective stabilization occurred , respectively , in 14 % and 44 % of the patients . Similarly , DC demonstrated a significantly superior subjective response rate ( partial plus complete ) of 82 % , compared to 48 % for CF . Patients with poor initial performance status or liver involvement had significantly lower response rates and reduced survival . Overall , there was no significant difference in survival between the two arms , reflecting the similarity between DC and CF in total objective response rate ( partial response plus stable disease ) . DC provided superior palliation and was well tolerated by an essentially geriatric population .
77045
Intervention_Physical
chemotherapy
77046
Intervention_Pharmacological
doxorubicin
77047
Intervention_Pharmacological
lomustine
77048
Intervention_Pharmacological
cyclophosphamide and 5-FU ( CF )
77049
Intervention_Pharmacological
CF
77050
Intervention_Pharmacological
DC
77051
Intervention_Pharmacological
CF
77052
Intervention_Pharmacological
DC
77053
Outcome_Other
tolerated
77054
Outcome_Physical
levels of myelosuppression
77055
Outcome_Other
objective partial response rate
77056
Outcome_Physical
Objective stabilization
77057
Outcome_Other
subjective response rate ( partial plus complete )
77058
Outcome_Other
response rates
77059
Outcome_Mortality
survival
77060
Outcome_Mortality
survival
77061
Outcome_Other
tolerated